Peter H. Schafer

TL;DR: Biophysical, biochemical and gene silencing studies show that CRBN is a proximate, therapeutically important molecular target of lenalidomid and pomalidomide.

TL;DR: The range of PDE4 isoforms, their role in signaling, their structural biology and related preclinical and clinical pharmacology are delineated, to provide potential, novel therapeutics for the treatment of inflammatory diseases and psoriasis.

TL;DR: In both populations, an unequivocal correlation between the number of culture-positive tissue samples and positive results of histologic analysis was noted, which corroborated the evidence that true infections were detected over the entire cultivation period.

TL;DR: This work presents a molecular model in which drug binding to cereblon results in the interaction of Ikaros and Aiolos to CRL4CRBN, leading to their ubiquitination, subsequent proteasomal degradation and T cell activation.

TL;DR: It is suggested that lenalidomide has the potential to enhance the rituximab-induced killing of NHL cell lines and primary B-cell chronic lymphocytic leukemia cells via a NK cell-mediated and monocyte-mediated ADCC mechanism in vitro, providing a strong rationale for the combination of lenalidumide with IgG1 antibodies to target tumor-specific antigens in patients with cancer.